The study was conducted in 23 patients and compared 3 mg and 6 mg MELT-210 sublingual midazolam tablets against an IV-administered comparator of midazolam.
The top-line data demonstrated that concentration comparisons between MELT-210 and the reference drug met the goals of the study.
MELT-210 is administered in a rapidly dissolving, sublingual tablet developed in partnership with Catalent, using its proprietary Zydis orally disintegrating tablet technology to create a tablet that dissolves quickly when placed under the tongue.
This technology has been used in over 35 NDA-approved products, spanning almost three decades.
Because of the uniqueness of Catalent's technology, no therapeutically equivalent product has been approved by the FDA for any of the previously NDA-approved products using Zydis.
Melt Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development and commercialization of patented non-intravenous and non-opioid sedation and analgesia medicines for medical procedures in outpatient and in-office settings.
Melt's core technology is a series of non-opioid sedation drug formulations that may replace or supplement current sedation and/or analgesia modalities for more than 100 m medical procedures in the United States.
Melt Pharmaceuticals, Inc. was carved out of Harrow Health, Inc. (NASDAQ: HROW) in 2019.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT